Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine).

Different liquisolid formulations of carbamazepine were accomplished by dissolving the drug in the non-toxic hydrophilic liquids, and adsorbing the solution onto the surface of silica. In order to reduce the amounts of carrier and aerosil in liquisolid formulations, some additives namely polyvinylpyrrolidone (PVP), hydroxypropyle methylcellulose (HPMC) and polyethylene glycol (PEG 35000) were added to liquid medication to increase loading factor. The effects of various ratios of carrier to coating material, PVP concentration, effect of aging and type of the carrier on dissolution rate of liquisolid compacts were studied. X-ray crystallography and differential scanning calorimetery (DSC) were used for evaluation of physicochemical properties of carbamazepine in liquisolid formulations. The results showed that the drug loading factor was increased significantly in the presence of additives. Liquisolid formulations containing PVP as additive, exhibited significantly higher drug dissolution rates compared to the compacts prepared by the direct compression technique. It was shown that microcrystalline cellulose had more liquid retention potential in comparison with lactose, and the formulations containing microcrystalline cellulose as carrier, showed higher dissolution rate. By decreasing the ratio of microcrystalline cellulose to silica from 20 to 10, an improvement in dissolution rate was observed. Further decrease in the ratio of microcrystalline cellulose:silica from 10 to 5 resulted in a significant reduction in dissolution rate. Increasing of PVP concentration in liquid medication caused a dramatic increase in dissolution rate at first 30min. The results showed that the dissolution rate of liquisolid tablets was not significantly affected by storing the tablets at 25 degrees C/75% relative humidity for a period of 6 months. The results of DSC and X-ray crystallography did not show any changes in crystallinity of the drug and interaction between carbamazepine and exipients during the process.

[1]  Kenji Nishimura,et al.  Inhibitory effects of water-soluble polymers on precipitation of RS-8359 , 1997 .

[2]  A. Dzyabchenko,et al.  X-ray characterization of the triclinic polymorph of carbamazepine. , 1997, Journal of pharmaceutical sciences.

[3]  R. Grover,et al.  Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. , 1999, Drug development and industrial pharmacy.

[4]  J. Ayres,et al.  Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. , 2001, International journal of pharmaceutics.

[5]  A. Nokhodchi,et al.  The effect of solvent and crystallization conditions on habit modification of Carbamazepine , 2001 .

[6]  A. Nokhodchi,et al.  Dissolution and mechanical behaviors of recrystallized carbamazepine from alcohol solution in the presence of additives , 2005 .

[7]  P. Finholt,et al.  Dissolution kinetics of drugs in human gastric juice--the role of surface tension. , 1968, Journal of pharmaceutical sciences.

[8]  A. Nokhodchi,et al.  Enhancement of dissolution rate of piroxicam using liquisolid compacts. , 2005, Farmaco.

[9]  Yousef Javadzadeh,et al.  The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. , 2005, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[10]  A. P. Lötter,et al.  Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine. , 1987, Journal of pharmaceutical sciences.

[11]  Spiro Spireas,et al.  Enhancement of prednisolone dissolution properties using liquisolid compacts , 1998 .

[12]  V. L. Himes,et al.  Structure of carbamazepine: 5H-dibenz[b,f]azepine-5-carboxamide , 1981 .

[13]  P. Costa,et al.  An alternative method to the evaluation of similarity factor in dissolution testing. , 2001, International journal of pharmaceutics.

[14]  A. Matzger,et al.  Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. , 2003, Journal of pharmaceutical sciences.

[15]  H. Abdou.  Dissolution, Bioavailability and Bioequivalence , 1990 .

[16]  An Investigation of Physicochemical Properties of Piroxicam Liquisolid Compacts , 2007, Pharmaceutical development and technology.

[17]  A. Aguiar,et al.  Deaggregation behavior of a relatively insoluble substituted benzoic acid and its sodium salt. , 1967, Journal of pharmaceutical sciences.

[18]  L. Lachman,et al.  Interdependence of physiological surfactant and drug particle size on the dissolution behavior of water insoluble drugs. , 1968, Journal of pharmaceutical sciences.

[19]  R. Grover,et al.  In vitro release evaluation of hydrocortisone liquisolid tablets. , 1998, Journal of pharmaceutical sciences.

[20]  Martin H. Abramson,et al.  Complete Drug Reference , 1996 .

[21]  W I Higuchi,et al.  Dissolution rates of high energy sulfathiazole--povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies. , 1976, Journal of pharmaceutical sciences.